Methods for treating neovascularization and intravitreal implants
0 Assignments
0 Petitions
Accused Products
Abstract
Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
-
Citations
8 Claims
-
1. (canceled)
- 2. An intravitreal, bioerodible drug delivery system comprising a steroid effective in preventing or reducing neovascularization in an eye prone to neovascularization, and a polylactic acid polyglycolic acid (PLGA) copolymer thereby forming an implant for placement into the vitreous of an eye prone to neovascularization.
- 5. An intravitreal, bioerodible drug delivery system comprising a steroid effective in preventing or reducing neovascularization in an eye prone to neovascularization, and a polylactic acid polyglycolic acid (PLGA) copolymer.
-
7. A method for treating neovascularization in an eye of an individual, the method comprising implanting in the vitreous of an eye prone to neovascularization an intravitreal, bioerodible drug delivery system comprising an immunosuppressive agent and a polylactic acid polyglycolic acid (PLGA) copolymer.
-
8. An intravitreal, bioerodible drug delivery system comprising particles of a drug, a polylactic acid polyglycolic acid (PLGA) copolymer, wherein the system is effective in releasing the drug into the eye over a period of at least about 3 weeks, and wherein the intravitreal, bioerodible drug delivery system is a single pellet or a single extruded filament.
Specification